IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans

J Allergy Clin Immunol. 2019 Dec;144(6):1731-1734.e1. doi: 10.1016/j.jaci.2019.08.014. Epub 2019 Aug 27.

Abstract

Ustekinumab is currently being explored for the treatment of alopecia areata. Here, our work in a murine model and in human patients indicates that neutralization of the IL-12 and IL-23 pathways does not ameliorate disease.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alopecia / drug therapy
  • Alopecia / immunology*
  • Alopecia / pathology
  • Animals
  • Antibodies, Neutralizing / immunology
  • Antibodies, Neutralizing / pharmacology*
  • Female
  • Humans
  • Interleukin-12 Subunit p40 / antagonists & inhibitors*
  • Interleukin-12 Subunit p40 / immunology
  • Interleukin-23 Subunit p19 / antagonists & inhibitors*
  • Interleukin-23 Subunit p19 / immunology
  • Male
  • Mice

Substances

  • Antibodies, Neutralizing
  • IL12B protein, human
  • IL23A protein, human
  • Il12b protein, mouse
  • Il23a protein, mouse
  • Interleukin-12 Subunit p40
  • Interleukin-23 Subunit p19